Coronary interventions

BioMatrix versus Orsiro biodegradable polymer stents in all-comer patients with coronary artery disease: the multicentre, randomised BIODEGRADE trial

EuroIntervention 2021;16:1404-1412. DOI: 10.4244/EIJ-D-20-00185

Chang-Hwan Yoon
Chang-Hwan Yoon1, MD; Young Jin Choi2, MD; Jin Joo Park1, MD; Si-Hyuck Kang1, MD; Sun-Hwa Kim1, PhD; Jung-Won Suh1, MD; Young-Seok Cho1, MD; Tae-Jin Youn1, MD; Myeong-Kon Kim3, MD; Kwang Soo Cha4, MD; Seung-Hwan Lee5, MD; Bum-Kee Hong6, MD; Seung-Woon Rha7, MD; Woong-Chol Kang8, MD; Jae-Hwan Lee9, MD; Sang-Hyun Kim10, MD; In-Ho Chae1
1. Seoul National University Bundang Hospital, Seongnam, Rebublic of Korea; 2. Sejong General Hospital, Bucheon, Republic of Korea; 3. Catholic Kwandong University International St. Mary’s Hospital, Incheon, Republic of Korea; 4. Pusan National University Hospital, Pusan, Republic of Korea; 5. Wonju Severance Hospital, Yonsei University College of Medicine, Seoul, Republic of Korea; 6. Gangnam Severance Hospital, Yonsei University College of Medicine, Seoul, Republic of Korea; 7. Korea University Guro Hospital, Seoul, Republic of Korea; 8. Gachon University Gil Medical Center, Incheon, Republic of Korea; 9. Chungnam National University Hospital, Daejeon, Republic of Korea; 10. Seoul Metropolitan Government Seoul National University Boramae Medical Center, Seoul, Republic of Korea

Aims: The aim of this trial was to compare the safety and efficacy of a thin-strut biodegradable polymer sirolimus-eluting cobalt-chromium stent (Orsiro) to a thick-strut biodegradable polymer biolimus-eluting stent (BioMatrix).

Methods and results: This randomised, open-label, non-inferiority trial was conducted among patients undergoing percutaneous coronary intervention. The primary endpoint was target lesion failure (TLF). Between July 2014 and September 2017, we randomly assigned 2,341 patients to BioMatrix stents (n=1,166) or Orsiro stents (n=1,175). We analysed 2,327 patients who completed 18-month follow-up. The mean patient age was 63.5 years, and 1,565 (67.3%) patients presented with acute coronary syndrome. At 18 months, 34 (2.9%) patients with BioMatrix stents and 24 (2.1%) with Orsiro stents experienced TLF (hazard ratio [HR] 0.70, upper limit of one-sided 95% confidence interval: 1.18, p for non-inferiority <0.0001). No significant differences were noted in rates of cardiac death (16 [1.4%] vs 12 [1.0%], p=0.558), target lesion-related myocardial infarction (0 [0%] vs 3 [0.3%], p=0.250), target lesion revascularisation (18 [1.6%] vs 10 [0.9%], p=0.124), or stent thrombosis (0 [0%] vs 2 [0.2%], p=0.50).

Conclusions: In patients with a high prevalence of acute coronary syndrome, Orsiro stents were not inferior to BioMatrix stents. Both showed good clinical outcomes.

Visual summary. Comparison of the BioMatrix and Orsiro stents: summary of 18-month outcomes. Aetiopathology of debris captured by cerebral embolic protection filters during TAVI, including risk factors for greater amounts or larger particles of debris.

Sign in to read and download the full article

Forgot your password?

No account yet?
Sign up for free!

Create my pcr account

Join us for free and access thousands of articles from EuroIntervention, as well as presentations, videos, cases from

acs/nste-acsdrug-eluting stentstable anginastemi
Coronary interventionsStents and scaffolds
Read next article
Clinical outcomes with unselected use of an ultrathin-strut sirolimus-eluting stent: a report from the Swedish Coronary Angiography and Angioplasty Registry (SCAAR)

Latest news